|Datasheet||Specific References||Reviews||Related Products||Protocols|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Cynomolgus monkey CD70 Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||CG90089-G-F|
|Cynomolgus monkey CD70 Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||CG90089-G-H|
|Cynomolgus monkey CD70 Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||CG90089-G-M|
|Cynomolgus monkey CD70 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||CG90089-G-N|
|Cynomolgus monkey CD70 Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||CG90089-G-Y|
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.